Combination Chemotherapy in Treating Patients With Lymphoma
Public ClinicalTrials.gov record NCT00002835. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
Study identification
- NCT ID
- NCT00002835
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 116 participants
Conditions and interventions
Conditions
Interventions
- Bleomycin Sulfate (BLM) Biological
- Filgrastim (G-CSF) Biological
- Recombinant Interferon Alfa Biological
- Carmustine Drug
- Cisplatin (CDDP) Drug
- Cyclophosphamide Drug
- Cytarabine (ARA-C) Drug
- Etoposide (VP-16) Drug
- Idarubicin Drug
- Ifosfamide Drug
- Leucovorin Calcium Drug
- Melphalan Drug
- Methotrexate Drug
- Methylprednisolone Drug
- mitoxantrone hydrochloride (DHAD) Drug
- Vincristine Sulfate Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Radiation Therapy Radiation
Biological · Drug · Procedure + 1 more
Eligibility (public fields only)
- Age range
- 15 Years to 59 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 1995
- Primary completion
- Feb 3, 2004
- Completion
- Feb 3, 2004
- Last update posted
- Nov 14, 2018
1995 – 2004
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Lymphoma trials
Other public records listing Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT04608487: Axi-cel in CNS Lymphoma Active, not recruiting
- NCT01441089: Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis Recruiting
- NCT07654426: The CARDIOPROTECT Trial Recruiting
- NCT04898790: Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant Recruiting
- NCT06563505: A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma Recruiting
- NCT05170399: Vaccine Responses in Patients With B Cell Malignancies Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002835, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00002835 live on ClinicalTrials.gov.